The presence of RBL2 loss of function in aggressive breast cancer subgroups and pancreatic cancer with the associated increase in WNT pathway components prompted us to test if RBL2 could regulate the activity of the WNT pathway in human breast and pancreatic tumours. Here, RBL2 is linked to pancreatic neoplasm.